跳至主要内容
临床试验/NCT02505945
NCT02505945已完成4 期

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

Torax Medical Incorporated21 个研究点 分布在 1 个国家目标入组 152 人开始时间: 2015年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
152
试验地点
21
主要终点
Elimination of Moderate-severe Regurgitation at 6 Months

研究概览

简要总结

This study compares mechanical sphincter augmentation (LINX Reflux Management System) to double-dose proton pump inhibitors (PPIs) for the management of reflux symptoms related to gastroesophageal reflux disease (GERD).

详细描述

Prospective, multicenter, 2:1 randomized, cross-over, two arms

  • Control arm: Double-dose PPI [Omeprazole 20 mg BID (twice a day)]
  • Treatment arm: LINX Reflux Management System Up to 20 study centers throughout the U.S. will participate. Approximately150 patients will be enrolled into the study. Subjects will be randomized 2:1 into the double-dose PPIs arm (100 subjects) and the LINX arm (50 subjects).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient seeks consultation for lack of satisfactory symptom response to once daily PPIs.
  • Age≥ 21 years old.
  • Abnormal distal esophageal pH determined by total % time pH <4 or DeMeester Score. Testing to be completed off GERD medications for at least 7 days, with the exception of antacids, which may be taken up until the morning of assessment.
  • Suitable surgical candidate (i.e. is able to undergo general anesthesia and laparoscopic surgery).
  • Patient has provided written informed consent for participation in the randomized study.

排除标准

  • Currently taking double-dose PPIs (twice daily dosing).
  • Hiatal hernia >3cm as determined by endoscopy.
  • Distal esophageal motility (average of sensors 3 and 4) is less than 35 mmHg peristaltic amplitude on wet swallows or <70% (propulsive) peristaltic sequences.
  • Esophagitis Grade C or D (Los Angeles classification).
  • Body mass index >
  • Diagnosed with an esophageal motility disorder LES.
  • Esophageal stricture or gross esophageal anatomic abnormalities
  • History of/or known Barrett's esophagus.
  • Suspected or known allergies to titanium, stainless steel, nickel or ferrous materials.

研究组 & 干预措施

Control Arm

Active Comparator

Double-dose PPI [Omeprazole 20 mg BID (twice a day)]

干预措施: Omeprazole (Drug)

Treatment Arm

Active Comparator

LINX Reflux Management System

干预措施: LINX Reflux Management System (Device)

结局指标

主要结局

Elimination of Moderate-severe Regurgitation at 6 Months

时间窗: 6 months

The primary endpoint was the percent of patients in both treatment arms who achieved elimination of moderate-severe regurgitation at 6 months, as reported on the foregut symptom questionnaire.

次要结局

  • Percentage of Subjects With ≥50% Reduction in Total Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) Scores(6 months)

研究者

发起方
Torax Medical Incorporated
申办方类型
Industry
责任方
Sponsor

研究点 (21)

Loading locations...

相似试验